Joyner, who heads CVS’s pharmacy-benefit business Caremark, will succeed Karen Lynch.

Cigna’s earnings beat Wall Street expectations, providing relief to investors who had soured on the struggles of insurers’ Medicare and Medicaid businesses. The company, parent of a health insurer and ...

The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...

Cigna surpassed Wall Street estimates for third-quarter profit on Thursday, driven by high demand for biosimilars of a ...

Pharmacy Benefit Services sales increased 50% to ... The adjusted EPS of $7.51, increased from $6.77 a year ago, beat the Wall Street estimate of $7.20. Guidance: Cigna reaffirms 2024 adjusted ...

NEW YORK (Reuters) - CVS Health's David Joyner is expected to address how he will better manage rising patient costs in the ...

after posting quarterly results that beat Wall Street expectations, driven by strong demand for its specialty drugs and new clients for its pharmacy benefit management unit. Shares of the U.S ...

Joyner, who is the president of the company's pharmacy benefit manager CVS Caremark ... Reuters reported earlier this week. The Wall Street Journal had first reported the news of Joyner's ...

Shares of the company tumbled 11% to $57 in premarket trading. Joyner, who is the president of the company's pharmacy benefit ...

In a September 25, 2024 editorial, The Wall Street Journal notes that if ... Advertisement Study after study has shown that Pharmacy Benefit Managers (PBMs) aggregate the purchasing power of ...

the Wall Street Journal reported on Friday. Joyner, who is the president of the company's pharmacy benefit manager CVS ...

That provides an explanation for Lynch's departure, and for investors previously calling for the company to break up, an outcome Joyner ruled out in an interview with the Wall Street Journal.